The 11-year long-term follow-up study from the randomized BENEFIT CIS trialLudwig Kappos, Christine Lebrun‐Frénay, Gilles Edan et al.|Neurology|2016Cited by 130
Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trialBruce Cree, Piotr Sokolowski, Gary Cutter et al.|The Lancet Neurology|2020Cited by 104
Serum Alpha-Linolenic Acid and Long-Term Multiple Sclerosis Activity and ProgressionMarianna Cortese, Tuula Pirttilä, Rupert Sandbrink et al.|Neurology|2025Cited by 3